Harryvan, Tom J. http://orcid.org/0000-0002-0386-8302
Golo, Matteo
Dam, Nicole
Schoonderwoerd, Mark J. A.
Farshadi, Elham Aida
Hornsveld, Marten
Hoeben, Rob C. http://orcid.org/0000-0001-9443-8377
Hawinkels, Lukas J. A. C.
Kemp, Vera http://orcid.org/0000-0003-4910-4655
Funding for this research was provided by:
Overleven met Alvleesklierkanker - SOAK 21.02 NWO-talent program Veni, ZonMw
Leids Universitair Medisch Centrum
Article History
Received: 18 March 2022
Revised: 13 June 2022
Accepted: 6 July 2022
First Online: 22 July 2022
Competing interests
: RCH and VK are named inventors of patents pertaining to the use of human and non-human primate-derived adenoviruses as oncolytic agents. RCH receives research funding from Janssen Vaccines & Prevention BV (Leiden, The Netherlands) for projects on adenoviruses. The funders had no role in the design of this study, in the collection, analyses, interpretation of data and in the writing of the manuscript.